Biotech / Medical
BTX BioTime
An SI Board Since July 2014
Posts SubjectMarks Bans Symbol
67 7 0 BTX
Emcee:  Savant Type:  Moderated
BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime's focus is on pluripotent stem cell technology based on human embryonic stem ("hES") cells and induced pluripotent stem ("iPS") cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime's therapeutic and research products include a wide array of proprietary PureStem(R) progenitors, HyStem(R) hydrogels, culture media, and differentiation kits. BioTime is developing Renevia(TM) (a HyStem(R) product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia(TM), in 2014. In addition, BioTime has developed Hextend(R) , a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend(R) is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
67 RT--Asterias/they might want to do a study of salamander radial glial stem cellSavant-November 2
66Asterias Announces Two Significant Developments for Spinal Cord Injury ProgSavant-October 2
65Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VASavant-September 26
64Asterias' AST-OPC1 Clinical Trial Will Continue as Planned Following ReSavant-September 25
63 ALAMEDA, Calif.--(BUSINESS WIRE)--September 14, 2017-- BioTime, Inc. (NYSE AmeSavant-September 14
62BioTime Inc. (BTX) filed a Form 8K - Changes to Articles of Incorporation or BylSavant-September 14
61 FREMONT, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, ISavant-September 6
60Asterias Biotherapeutics Reports Second Quarter Financial Results and Reviews ReSavant-August 16
59AST Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial Savant-August 9
58AST Former Quadriplegic Enrolled in Asterias' SCiStar Study to Throw CeremoSavant-August 8
57Asterias Biotherapeutics Opens Two Additional Clinical Sites for AST-OPC1 SCiStaSavant-August 3
56 AST ... Ability to enroll patients with second most common cervical spinal corSavant-July 10
55 Presentation by AST today 9 mon. results slides @ link Third patient recovers Savant-June 13
54Further great news for spinal injury patients.. Update on Full Six-Patient CohSavant-March 21
53 BTX & OCX BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte SSavant-February 22
52BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company deSavant-February 15
51 BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Savant-February 6
50AST - AST.WS Asterias Biotherapeutics Extends the Expiration Date of Certain WSavant-February 3
49 BioTime to Present at Noble Capital Markets Thirteenth Annual Investor ConferenSavant-January 26
48Additional Data From BioTimes OpRegen(R) Clinical Trial in Dry-AMD to be PresentSavant-January 19
47 Asterias Announces Successful Commencement of Operations at New GMP ManufacturiSavant-January 9
46 BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell TheraSavant-January 3
45 Ascendance Biotechnology Licenses the Right to Manufacture, Market and Sell CytSavant-12/28/2016
44BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial Dec 14,Savant-12/14/2016
43BioTime to Present at Global Bioproduction Summit Dec 12, 2016 07:00:00 (ET) CSavant-12/12/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.